Compared with the approved combination regimen like the use of CTLA‐4 and PD‐1 inhibitors in melanoma,[36] which showed limited efficacy in other cancer types, sequential therapy using CDK4/6i and PD‐1 inhibitors may reduce the side effects associated with the concurrent use of two immune checkpoint inhibitors, such as immune‐related adverse events (irAEs) and have shown efficacy in various cancers, such as breast cancer,[37] and sequential PD‐1 therapy may expand their application scope. The gene discussed is CTLA4; the disease is breast cancer.